Stoke Therapeutics, Inc. Segment Reporting Other Item Amount
Stoke Therapeutics, Inc. (STOK) reported Segment Reporting Other Item Amount of -$13.71 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Notes › Segment Reporting
us-gaap:SegmentReportingOtherItemAmount · last filed 2026-03-16
- Stoke Therapeutics, Inc. segment reporting other item amount for the quarter ending 2025-12-31 was -$3.50M.
- Stoke Therapeutics, Inc. segment reporting other item amount for the quarter ending 2025-09-30 was -$4.74M.
- Stoke Therapeutics, Inc. segment reporting other item amount for the quarter ending 2025-06-30 was -$3.82M.
- Stoke Therapeutics, Inc. segment reporting other item amount for the quarter ending 2025-03-31 was -$1.64M.
- Stoke Therapeutics, Inc. segment reporting other item amount for fiscal 2025 was -$13.71M.
- Stoke Therapeutics, Inc. segment reporting other item amount for fiscal 2024 was -$12.39M.
- Stoke Therapeutics, Inc. segment reporting other item amount for fiscal 2023 was -$10.07M.
| Period end | Segment Reporting Other Item Amount 3 month | Segment Reporting Other Item Amount 6 month | Segment Reporting Other Item Amount 9 month | Segment Reporting Other Item Amount 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$3.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$8.25M derived: sum of 2 quarters · filed 2026-03-16 | -$12.07M derived: sum of 3 quarters · filed 2026-03-16 | -$13.71M 10-K · filed 2026-03-16 |
| 2025-09-30 | -$4.74M 10-Q · filed 2025-11-04 | -$8.56M derived: sum of 2 quarters · filed 2025-11-04 | -$10.20M 10-Q · filed 2025-11-04 | -$13.37M derived: sum of 4 quarters · filed 2026-03-16 |
| 2025-06-30 | -$3.82M 10-Q · filed 2025-08-12 | -$5.46M 10-Q · filed 2025-08-12 | -$8.63M derived: sum of 3 quarters · filed 2026-03-16 | -$12.20M derived: sum of 4 quarters · filed 2026-03-16 |
| 2025-03-31 | -$1.64M 10-Q · filed 2025-05-13 | -$4.81M derived: sum of 2 quarters · filed 2026-03-16 | -$8.38M derived: sum of 3 quarters · filed 2026-03-16 | -$12.03M derived: sum of 4 quarters · filed 2026-03-16 |
| 2024-12-31 | -$3.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$6.74M derived: sum of 2 quarters · filed 2026-03-16 | -$10.39M derived: sum of 3 quarters · filed 2026-03-16 | -$12.39M 10-K · filed 2026-03-16 |
| 2024-09-30 | -$3.57M 10-Q · filed 2025-11-04 | -$7.22M derived: sum of 2 quarters · filed 2025-11-04 | -$9.22M 10-Q · filed 2025-11-04 | |
| 2024-06-30 | -$3.65M 10-Q · filed 2025-08-12 | -$5.64M 10-Q · filed 2025-08-12 | ||
| 2024-03-31 | -$2.00M 10-Q · filed 2025-05-13 | |||
| 2023-12-31 | -$10.07M 10-K · filed 2025-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |